1Ayusawa M, Sonobe T, Uemura S, Nakamura Y, Ogawa S, Kiyosa- wa N. Revision of diagnostic guidelines for Kawasaki disease( the 5th revised edition)[J]. Pediatr Int, 2005, 47(2) : 232-234.
2Esper F, Shapiro ED, Weibel C, Ferguson D, Landry ML, Kahn JS. Association between a novel human coronavirus and Kawasaki disease[J]. J Infect Dis, 2005, 191(4): 499-502.
3Yeung RSM. The etiology of Kawasaki disease: a superantigen-me- diated process[J]. Prog Pediatr Cardiol, 2004, 19(2) : 115-122.
4Yeung RS. Pathogenesis and treatment of Kawasaki's disease[ J ]. Curr Opin Rheumatol, 2005, 17(5) : 617-623.
6Lin CY, Lin CC, Hwang B, Chiang B. Serial changes of serum interleukin-6, interleukin-8, and tumor necrosis factor alpha among patients with Kawasaki disease[ J]. J Pediatr, 1992, 121 (6) : 924-926.
7Igarashi H, Hatake K, Tomizuka H, Yarnada M, Gunji Y, Momoi MY. High serum level of M-CSF and G-CSF in Kawasaki disease [J]. Br J Hematol, 1999, 105(3):613-615.
8Suzuki H, Noda E, Miyawaki M, Takeuchi T, Uemura S, Koike M. Serum levels of neutrophil activation cytokines in Kawasaki disease[J]. Pediatr Int, 2001, 43(2) : 115-119.
9Onouchi Z, Hamaoka K, Ozawa S, Sakata K, Kiyosawa N, Ito H. Neutropenia in the acute phase of Kawasaki disease and pre- vention of coronary artery aneurysm [ J ]. Pediatr Int, 2009, 51 (4) : 448-452.
10Tsujimoto H, Takeshita S, Nakatani K, Kawamura Y, Tokutomi T, Sekine I. Intravenous immunoglobulin therapy induces neutro- phil apoptosis in Kawasaki disease[ J]. Clin Immunol, 2002,103 (2) : 161-168.
4Fukazawa R, Ogawa S. Long-term prognosis of patients with Kawasaki disease: at risk for future atherosclerosis [ J]. J Nippon Med Sch, 2009, 76(3) :124-133.
5KD Codispoti C, Boyd S, Sees D, Conner W. Symptomatic coronary obstruction due to Kawasaki disease in an adult [ J]. Ann Thorac Surg, 2008, 85(3) : 1081-1083.
6Nakamura Y, Yashiro M, Uehara R, Watanabe M, Tajimi M, Oki I, et al. Case-control study of giant coronary aneurysms due to Kawasaki disease[J]. Pediatr Int, 2003, 45(4) : 410-413.
7Newburger JW, Sleeper LA, McCrindle BW, Minich LL, Gersony W, Vetter VL, et al. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease [ J]. N Engl J Med, 2007, 356(7) :663-675.
8Burns JC. The riddle of Kawasaki disease [ J ]. N Engl J Med, 2007, 356(7) :659-661.
9Tsuda E, Kamiya T, Ono Y, Kimura K, Echigo S. Dilated coronary arterial lesions in the late period after Kawasaki disease [ J ]. Heart, 2005, 91(2) :177-182.
10Kato H, Sugimura T, Akagi T, Sato N, Hashino K, Maeno Y, et al. Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients [ J ]. Circulation, 1996, 94 (6) : 1379-1385.
4Nakamura Y, Yashiro M, Uehara R, et al. Epidemiologic features of kawasaki disease in Japan: results of the 2009--2010 nationwide survey. Epidemiol, 2012, 22: 216-221.
5Gardner-Medwin JMM, Dolezalova P, Cummins C, et al. Incidence of Henoch-Schonle in purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet, 2002, 360: 1197-1202.
6Mamoru A, Tomoyoshi S, Shigeru U, et al. Revision of di- agnostic guidelines of Kawasaki disease, infantile acute febrile mucocutaneous lymphnodes syndrome (the 5th Ed). Pediatfr Int, 2005, 47: 232-234.
7Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease. Circulation, 2004, 110: 2747-2771.
9Onouchi Z, Hamaoka K, Ozawa S, et al. Neutropenia in the acute phase of Kawasaki disease and prevention of coronary artery aneurysm. Pediatr Int, 2009, 51 : 448-452.
